Preparative HPLC purification (revision 9)

Preparative HPLC purification applies the chromatography of reverse-phase separation at a scale intended to collect material rather than to analyse it. For synthetic peptides it is the step that converts a crude product into a usable one, and it is typically the most expensive stage of manufacture.^[1]

The governing trade-off is yield against purity. Collecting a narrow window around the peak apex gives high purity and discards a substantial fraction of the product; collecting more widely recovers more material and includes more of the shoulders where impurities elute. Where the cut is made is a commercial decision as much as a technical one.^[2]

Because peptide impurities are structurally similar to the peptide, they elute close to it, and the separation problem grows harder as the target purity rises. The difference in cost between 95% and 99% material is not proportional to the difference in the numbers.^[1]

Moving from analytical to preparative scale increases column diameter and loading while keeping the chemistry constant. Linear velocity is preserved rather than volumetric flow, so flow rates rise with the square of the diameter, and mobile-phase consumption rises with them — the dominant recurring cost.^[2]

Loading is limited by overload. As the mass injected rises, peaks broaden and distort and resolution falls, so the practical loading is set by how much distortion the required purity tolerates. Touching-band operation, in which adjacent peaks just meet, is the usual economic optimum.

Fraction collection may be time-based or triggered by detector signal. Detector signals saturate at preparative loadings, so collection windows are often set by prior experiment rather than by real-time response, and a shift in retention between runs then costs yield or purity.^[3]

Collected fractions are pooled, and the pooling decision determines the composition of the lot. A pool assembled from central fractions differs from one that includes edge fractions, and both may be described by the same product name.^[1]

Solvent is removed and the peptide isolated, usually by lyophilisation. Because the mobile phase contains trifluoroacetic acid, the isolated solid is a trifluoroacetate salt unless a salt-exchange step is performed, and the counterion contributes mass that is not peptide — see Peptide content.